首页 > 最新文献

02.01 - Acute critical care最新文献

英文 中文
COVID-19 pneumonia hospitalizations in different phases of the pandemic in the United States: patient characteristics and clinical outcomes 美国疫情不同阶段COVID-19肺炎住院情况:患者特征和临床结果
Pub Date : 2023-03-09 DOI: 10.1183/23120541.lsc-2023.39
E. Mozaffari, A. Kalil, A. Chandak, H. Jiang, R. Gottlieb, E. Lee, C. Der-Torossian, S. Hollemeersch, M. Thrun, C. Chima-Melton
{"title":"COVID-19 pneumonia hospitalizations in different phases of the pandemic in the United States: patient characteristics and clinical outcomes","authors":"E. Mozaffari, A. Kalil, A. Chandak, H. Jiang, R. Gottlieb, E. Lee, C. Der-Torossian, S. Hollemeersch, M. Thrun, C. Chima-Melton","doi":"10.1183/23120541.lsc-2023.39","DOIUrl":"https://doi.org/10.1183/23120541.lsc-2023.39","url":null,"abstract":"","PeriodicalId":289883,"journal":{"name":"02.01 - Acute critical care","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126730447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
C3a and C5b-9 levels differentially predict COVID-19 severity and mortality. C3a和C5b-9水平预测COVID-19严重程度和死亡率存在差异。
Pub Date : 2022-09-04 DOI: 10.1183/13993003.congress-2022.2093
M. Detsika, E. Diamanti, K. Ampelakiotou, E. Jahaj, S. Tsipilis, N. Athanasiou, A. Zacharis, I. Dimopoulou, S. Orfanos, A. Tsirogianni, A. Kotanidou
{"title":"C3a and C5b-9 levels differentially predict COVID-19 severity and mortality.","authors":"M. Detsika, E. Diamanti, K. Ampelakiotou, E. Jahaj, S. Tsipilis, N. Athanasiou, A. Zacharis, I. Dimopoulou, S. Orfanos, A. Tsirogianni, A. Kotanidou","doi":"10.1183/13993003.congress-2022.2093","DOIUrl":"https://doi.org/10.1183/13993003.congress-2022.2093","url":null,"abstract":"","PeriodicalId":289883,"journal":{"name":"02.01 - Acute critical care","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117192231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improved atelectasis and lung homogeneity with diaphragm neurostimulation during mechanical ventilation in pigs with ARDS 机械通气期间膈神经刺激改善ARDS猪肺不张和肺均匀性
Pub Date : 2022-09-04 DOI: 10.1183/13993003.congress-2022.1023
E. Rohrs, T. Bassi, K. Fernandez, J. Wittmann, M. Nicholas, M. Ornowska, M. Gani, S. Reynolds
{"title":"Improved atelectasis and lung homogeneity with diaphragm neurostimulation during mechanical ventilation in pigs with ARDS","authors":"E. Rohrs, T. Bassi, K. Fernandez, J. Wittmann, M. Nicholas, M. Ornowska, M. Gani, S. Reynolds","doi":"10.1183/13993003.congress-2022.1023","DOIUrl":"https://doi.org/10.1183/13993003.congress-2022.1023","url":null,"abstract":"","PeriodicalId":289883,"journal":{"name":"02.01 - Acute critical care","volume":"46 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123290067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
STUMBL score for emergency department safe discharge of patients with minor blunt thoracic trauma STUMBL评分对轻度钝性胸外伤患者急诊室安全出院的影响
Pub Date : 2022-09-04 DOI: 10.1183/13993003.congress-2022.1628
J. Giamello, G. Martini, D. Prato, M. Santoro, Y. Arese, L. Bertolaccini, R. Melchio, C. Battle, T. Driscoll, A. Bono, A. Poggi, A. Bruno, A. Falcetta, A. Sciolla, C. Fulcheri, D. Caruso, G. Lauria
{"title":"STUMBL score for emergency department safe discharge of patients with minor blunt thoracic trauma","authors":"J. Giamello, G. Martini, D. Prato, M. Santoro, Y. Arese, L. Bertolaccini, R. Melchio, C. Battle, T. Driscoll, A. Bono, A. Poggi, A. Bruno, A. Falcetta, A. Sciolla, C. Fulcheri, D. Caruso, G. Lauria","doi":"10.1183/13993003.congress-2022.1628","DOIUrl":"https://doi.org/10.1183/13993003.congress-2022.1628","url":null,"abstract":"","PeriodicalId":289883,"journal":{"name":"02.01 - Acute critical care","volume":"157 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122458516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A pilot trial for ozanimod therapy in hospitalized COVID-19 patients ozanimod治疗住院COVID-19患者的试点试验
Pub Date : 2022-09-04 DOI: 10.1183/13993003.congress-2022.520
D. Marsolais, N. Châteauvert, P. Blais-Lecours, P. Rola, T. Nguyen, F. Lellouche
Background: Sphingosine-1-phosphate (S1P) receptor ligands reduce lung damage and endothelial activation in models of virus-induced pneumonia. Feasibility of initiating S1P receptor ligand therapy during pneumonia needs confirmation. Objective(s): Evaluate safety/efficacy outcomes of ozanimod therapy in COVID-19 patients. Method(s): In a prospective multicentric open-label pilot trial, adults with COVID-19 requiring O were recruited (3 Canadian centres, starting Sept. 2020). Patients were randomized to standard of care (SOC) or SOC + ozanimod (per os). Modified WHO-adapted 6-points ordinal scale for clinical improvement was computed daily and adverse events were recorded. Result(s): As of Jan. 2022, 41 patients (out of 48) were enrolled and 18 received ozanimod. Stratification at randomization balanced groups for risk factors of poor outcome and initial O2 requirement. No serious drug reaction was reported. Asymptomatic bradycardia occurred with ozanimod. So far, 36 patients completed the study-ending phone call (day 90). Ordinal scale-related outcomes are shown in Table 1. Since enrollment is ongoing, data is shown for the whole cohort. Conclusion(s): This small scale trial provides the very first evidence supporting the possibility of initiating S1P receptor ligand therapy during active COVID-19 pneumonia.
背景:鞘氨醇-1-磷酸(S1P)受体配体可减轻病毒诱导肺炎模型的肺损伤和内皮细胞活化。肺炎期间启动S1P受体配体治疗的可行性有待证实。目的:评价ozanimod治疗COVID-19患者的安全性/有效性。方法:在一项前瞻性多中心开放标签试点试验中,招募了COVID-19要求O的成年人(从2020年9月开始的3个加拿大中心)。患者随机分为标准治疗组(SOC)或SOC + ozanimod组(per os)。每日计算经世卫组织修订的临床改善6分顺序量表,并记录不良事件。结果:截至2022年1月,41名患者(48名)入组,18名患者接受了ozanimod。在随机平衡组中分层不良结局的危险因素和初始氧需要量。未见严重药物反应。奥扎尼莫德可发生无症状性心动过缓。到目前为止,36名患者完成了研究结束电话(第90天)。有序量表相关结果见表1。由于登记仍在进行中,因此显示了整个队列的数据。结论:这项小规模试验提供了第一个证据,支持在活动性COVID-19肺炎期间启动S1P受体配体治疗的可能性。
{"title":"A pilot trial for ozanimod therapy in hospitalized COVID-19 patients","authors":"D. Marsolais, N. Châteauvert, P. Blais-Lecours, P. Rola, T. Nguyen, F. Lellouche","doi":"10.1183/13993003.congress-2022.520","DOIUrl":"https://doi.org/10.1183/13993003.congress-2022.520","url":null,"abstract":"Background: Sphingosine-1-phosphate (S1P) receptor ligands reduce lung damage and endothelial activation in models of virus-induced pneumonia. Feasibility of initiating S1P receptor ligand therapy during pneumonia needs confirmation. Objective(s): Evaluate safety/efficacy outcomes of ozanimod therapy in COVID-19 patients. Method(s): In a prospective multicentric open-label pilot trial, adults with COVID-19 requiring O were recruited (3 Canadian centres, starting Sept. 2020). Patients were randomized to standard of care (SOC) or SOC + ozanimod (per os). Modified WHO-adapted 6-points ordinal scale for clinical improvement was computed daily and adverse events were recorded. Result(s): As of Jan. 2022, 41 patients (out of 48) were enrolled and 18 received ozanimod. Stratification at randomization balanced groups for risk factors of poor outcome and initial O2 requirement. No serious drug reaction was reported. Asymptomatic bradycardia occurred with ozanimod. So far, 36 patients completed the study-ending phone call (day 90). Ordinal scale-related outcomes are shown in Table 1. Since enrollment is ongoing, data is shown for the whole cohort. Conclusion(s): This small scale trial provides the very first evidence supporting the possibility of initiating S1P receptor ligand therapy during active COVID-19 pneumonia.","PeriodicalId":289883,"journal":{"name":"02.01 - Acute critical care","volume":"75 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117000473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Awake Prone Positioning in Acute Hypoxemic Respiratory Failure from COVID-19: A Randomized Clinical Trial 醒着俯卧位治疗COVID-19急性低氧性呼吸衰竭:一项随机临床试验
Pub Date : 2022-09-04 DOI: 10.1183/13993003.congress-2022.3107
W. Alhazzani, K. Parhar, J. Weatherald, Z. Al Duhailib, M. Alshahrani, A. Al-Fares, S. Buabbas, S. Cherian, L. Munshi, E. Fan, F. Al-Hameed, J. Chalabi, A. Rahmatullah, E. Duan, J. Tsang, K. Lewis, F. Lauzier, J. Centofanti, B. Rochwerg, S. Culgin, K. Nelson, S. Abdukahil, K. Fiest, H. Stelfox, H. Tlayjeh, M. Meade, D. Perri, K. Solverson, D. Niven, R. Lim, M. Møller, E. Belley-Côté, L. Thabane, H. Tamim, D. Cook, Y. Arabi
{"title":"Awake Prone Positioning in Acute Hypoxemic Respiratory Failure from COVID-19: A Randomized Clinical Trial","authors":"W. Alhazzani, K. Parhar, J. Weatherald, Z. Al Duhailib, M. Alshahrani, A. Al-Fares, S. Buabbas, S. Cherian, L. Munshi, E. Fan, F. Al-Hameed, J. Chalabi, A. Rahmatullah, E. Duan, J. Tsang, K. Lewis, F. Lauzier, J. Centofanti, B. Rochwerg, S. Culgin, K. Nelson, S. Abdukahil, K. Fiest, H. Stelfox, H. Tlayjeh, M. Meade, D. Perri, K. Solverson, D. Niven, R. Lim, M. Møller, E. Belley-Côté, L. Thabane, H. Tamim, D. Cook, Y. Arabi","doi":"10.1183/13993003.congress-2022.3107","DOIUrl":"https://doi.org/10.1183/13993003.congress-2022.3107","url":null,"abstract":"","PeriodicalId":289883,"journal":{"name":"02.01 - Acute critical care","volume":"194 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117084463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
To assess the diagnostic and prognostic ability of CXRs in COVID-19 pneumonitis 评价cxr对COVID-19肺炎的诊断和预后能力
Pub Date : 2022-09-04 DOI: 10.1183/13993003.congress-2022.4254
H. Ahmad, S. Soman, R. Varghese, K. Dewan, R. Chapman, J. Tong, R. Kumari, U. Ekeowa, R. Ragatha, P. Russell, S. Kuckreja, M. Long, M. Anwar
{"title":"To assess the diagnostic and prognostic ability of CXRs in COVID-19 pneumonitis","authors":"H. Ahmad, S. Soman, R. Varghese, K. Dewan, R. Chapman, J. Tong, R. Kumari, U. Ekeowa, R. Ragatha, P. Russell, S. Kuckreja, M. Long, M. Anwar","doi":"10.1183/13993003.congress-2022.4254","DOIUrl":"https://doi.org/10.1183/13993003.congress-2022.4254","url":null,"abstract":"","PeriodicalId":289883,"journal":{"name":"02.01 - Acute critical care","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124550058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of combined non-invasive support strategies use during acute respiratory failure due to COVID-19. COVID-19急性呼吸衰竭期间联合使用无创支持策略的影响
Pub Date : 2022-09-04 DOI: 10.1183/13993003.congress-2022.4043
J. Marín Corral, F. Parrilla, M. Restrepo, S. Pascual-Guardia, A. Rodríguez, J. C. Ballesteros, S. Sancho, L. Socias, E. Diaz, A. Albaya-Moreno, J. Masclans
Objectives: To evaluate the impact of combined non-invasive support strategies in critically ill COVID-19 patients [high-flow nasal cannula (HFNC), non-invasive ventilation (NIV) or both]. Method(s): Prospective observational multicenter study in 73 Spanish ICU with data obtained from the SEMICYUC registry. All confirmed COVID-19 patients admitted due to respiratory failure were included. They were classified according to the ventilatory strategy used on admission and subsequently according to success, failure, or strategy change. Demographic data, comorbidities, severity at admission, respiratory, biomarkers, failure, length of stay and mortality were evaluated. Result(s): We analyzed 3,889 patients, 33% receiving HFNC, and 11% NIV at ICU admission. NIV group compared to HFNC were more severely ill with more shock on admission. When NIV was received as a first-choice higher failure rates and mortality were shown vs HFNC (68% vs 61%, p=0.016 and 27% vs 20%, p=0.003). Among patients who initially received HFNC, 57% failed and 7.4% switched to NIV, with no change in mortality. Among patients who were switched to NIV, 66% failed presenting a higher mortality trend than the intubated patients after the HFNC starting (40% vs 30%, p=0.098). Among patients who initially received NIV, 60% failed and 20% switched to HFNC. Patients in whom NIV was switched to HFNC, had lower mortality than patients who initially failed (18% vs 40%, p<0.001). Among patients who were switched to HFNC, 43% failed, presenting the same mortality as the intubated patients after the NIV starting (38% vs 38%, p=0.934). Conclusion(s): Patients receiving NIV at admission have worse outcomes than those receiving HFNC. Changing the strategy in patients who received HFNC as a first choice without success can worsen the prognosis.
目的:评价联合无创支持策略[高流量鼻插管(HFNC)、无创通气(NIV)或两者结合]对危重症COVID-19患者的影响。方法:前瞻性观察性多中心研究,73个西班牙ICU的数据来自SEMICYUC注册表。纳入所有因呼吸衰竭而入院的新冠肺炎确诊患者。根据入院时使用的通气策略以及随后的成功、失败或策略改变进行分类。评估了人口统计数据、合并症、入院时严重程度、呼吸系统、生物标志物、衰竭、住院时间和死亡率。结果:我们分析了3,889例患者,33%在ICU入院时接受HFNC, 11%接受NIV。与HFNC组相比,NIV组病情更严重,入院时休克更多。当NIV作为首选时,失败率和死亡率高于HFNC(68%对61%,p=0.016, 27%对20%,p=0.003)。在最初接受HFNC的患者中,57%的患者失败,7.4%的患者改用NIV,死亡率没有变化。在切换为NIV的患者中,66%的患者在HFNC开始后失败,死亡率趋势高于插管患者(40% vs 30%, p=0.098)。在最初接受NIV的患者中,60%失败,20%改用HFNC。将NIV转换为HFNC的患者死亡率低于最初失败的患者(18% vs 40%, p<0.001)。在切换到HFNC的患者中,43%的患者失败,与插管患者在NIV开始后的死亡率相同(38% vs 38%, p=0.934)。结论:入院时接受NIV治疗的患者预后差于接受HFNC治疗的患者。对于接受HFNC作为第一选择而没有成功的患者,改变策略可能会使预后恶化。
{"title":"Impact of combined non-invasive support strategies use during acute respiratory failure due to COVID-19.","authors":"J. Marín Corral, F. Parrilla, M. Restrepo, S. Pascual-Guardia, A. Rodríguez, J. C. Ballesteros, S. Sancho, L. Socias, E. Diaz, A. Albaya-Moreno, J. Masclans","doi":"10.1183/13993003.congress-2022.4043","DOIUrl":"https://doi.org/10.1183/13993003.congress-2022.4043","url":null,"abstract":"Objectives: To evaluate the impact of combined non-invasive support strategies in critically ill COVID-19 patients [high-flow nasal cannula (HFNC), non-invasive ventilation (NIV) or both]. Method(s): Prospective observational multicenter study in 73 Spanish ICU with data obtained from the SEMICYUC registry. All confirmed COVID-19 patients admitted due to respiratory failure were included. They were classified according to the ventilatory strategy used on admission and subsequently according to success, failure, or strategy change. Demographic data, comorbidities, severity at admission, respiratory, biomarkers, failure, length of stay and mortality were evaluated. Result(s): We analyzed 3,889 patients, 33% receiving HFNC, and 11% NIV at ICU admission. NIV group compared to HFNC were more severely ill with more shock on admission. When NIV was received as a first-choice higher failure rates and mortality were shown vs HFNC (68% vs 61%, p=0.016 and 27% vs 20%, p=0.003). Among patients who initially received HFNC, 57% failed and 7.4% switched to NIV, with no change in mortality. Among patients who were switched to NIV, 66% failed presenting a higher mortality trend than the intubated patients after the HFNC starting (40% vs 30%, p=0.098). Among patients who initially received NIV, 60% failed and 20% switched to HFNC. Patients in whom NIV was switched to HFNC, had lower mortality than patients who initially failed (18% vs 40%, p<0.001). Among patients who were switched to HFNC, 43% failed, presenting the same mortality as the intubated patients after the NIV starting (38% vs 38%, p=0.934). Conclusion(s): Patients receiving NIV at admission have worse outcomes than those receiving HFNC. Changing the strategy in patients who received HFNC as a first choice without success can worsen the prognosis.","PeriodicalId":289883,"journal":{"name":"02.01 - Acute critical care","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128062644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ventilator alarms that received no intervention:an analysis of ventilator alarm relationship in intensive care unit 未干预的呼吸机报警:重症监护病房呼吸机报警关系分析
Pub Date : 2022-09-04 DOI: 10.1183/13993003.congress-2022.1240
C. Yujen, C. Shuhua, H. Yaochuan
{"title":"Ventilator alarms that received no intervention:an analysis of ventilator alarm relationship in intensive care unit","authors":"C. Yujen, C. Shuhua, H. Yaochuan","doi":"10.1183/13993003.congress-2022.1240","DOIUrl":"https://doi.org/10.1183/13993003.congress-2022.1240","url":null,"abstract":"","PeriodicalId":289883,"journal":{"name":"02.01 - Acute critical care","volume":"180 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126012299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Higher Crystalloids Volumes Predict Adverse Outcomes in Emergency Department Patients with Blunt Thoracic Trauma 更高的晶体体积预测急诊科钝性胸部创伤患者的不良结局
Pub Date : 2022-09-04 DOI: 10.1183/13993003.congress-2022.1634
G. Martini, J. Giamello, P. Crida, Y. Arese, L. Bertolaccini, S. Abram, E. Basile, E. Bernardi, F. Morra, F. Corsini, F. Tosello, G. Sobrero, G. Greco, L. Barutta, M. Bironzo, G. Lauria
{"title":"Higher Crystalloids Volumes Predict Adverse Outcomes in Emergency Department Patients with Blunt Thoracic Trauma","authors":"G. Martini, J. Giamello, P. Crida, Y. Arese, L. Bertolaccini, S. Abram, E. Basile, E. Bernardi, F. Morra, F. Corsini, F. Tosello, G. Sobrero, G. Greco, L. Barutta, M. Bironzo, G. Lauria","doi":"10.1183/13993003.congress-2022.1634","DOIUrl":"https://doi.org/10.1183/13993003.congress-2022.1634","url":null,"abstract":"","PeriodicalId":289883,"journal":{"name":"02.01 - Acute critical care","volume":"68 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130140707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
02.01 - Acute critical care
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1